雷公藤甲素
前药
医学
体内
药理学
癌症
胰腺癌
癌细胞
癌症研究
化学
细胞凋亡
内科学
生物
生物化学
生物技术
作者
Pawan Noel,Daniel D. Von Hoff,Ashok K. Saluja,Mohana Velagapudi,Erkut Borazanci,Haiyong Han
标识
DOI:10.1016/j.tips.2019.03.002
摘要
Triptolide, a compound isolated from a Chinese medicinal herb, possesses potent antitumor, immunosuppressive, and anti-inflammatory properties, but is clinically limited due to its poor solubility, bioavailability, and toxicity. Recently, Minnelide, a water-soluble prodrug of triptolide, was shown to have potent antitumor activity in various preclinical cancer models. Minnelide is currently in Phase II clinical trials for treatment of advanced pancreatic cancer, which has fueled increased interest in this promising agent. Here, we review the recent advances in the biological activity of triptolide and its analogs, their mechanisms of actions, and their clinical developments. A special emphasis is given to proteins and pathways within the tumor and stromal compartments that are targeted by triptolide and its analogs as well as the ongoing clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI